@HeartOTXHeartMD @JACCJournals Good to see more recognition/studies - CAR-T volumes keep rising with on going studies looking at new indications - will become a more prevalent consult ? for cardio-onc docs - our study on a smaller sample size had roughly 1
RT @RShouval: Cardiomyopathy post-CAR more common than we thought. 187 pts; 94% treated with axi-cel; 10% with new or worsening cardiomyopa…
RT @RShouval: Cardiomyopathy post-CAR more common than we thought. 187 pts; 94% treated with axi-cel; 10% with new or worsening cardiomyopa…
RT @RShouval: Cardiomyopathy post-CAR more common than we thought. 187 pts; 94% treated with axi-cel; 10% with new or worsening cardiomyopa…
Chimeric Antigen Receptor T-Cell Therapy-Associated Cardiomyopathy in Patients With Refractory or Relapsed Non-Hodgkin Lymphoma - PubMed https://t.co/AOhpmSULQv via @nuzzel
RT @RShouval: Cardiomyopathy post-CAR more common than we thought. 187 pts; 94% treated with axi-cel; 10% with new or worsening cardiomyopa…
RT @RShouval: Cardiomyopathy post-CAR more common than we thought. 187 pts; 94% treated with axi-cel; 10% with new or worsening cardiomyopa…
RT @RShouval: Cardiomyopathy post-CAR more common than we thought. 187 pts; 94% treated with axi-cel; 10% with new or worsening cardiomyopa…
RT @adsouza_md: important paper by @SarjuGanatraMD and colleagues. #CardioOncology https://t.co/5TmhKd9u1w
important paper by @SarjuGanatraMD and colleagues. #CardioOncology
RT @RShouval: Cardiomyopathy post-CAR more common than we thought. 187 pts; 94% treated with axi-cel; 10% with new or worsening cardiomyopa…
RT @RShouval: Cardiomyopathy post-CAR more common than we thought. 187 pts; 94% treated with axi-cel; 10% with new or worsening cardiomyopa…
RT @RShouval: Cardiomyopathy post-CAR more common than we thought. 187 pts; 94% treated with axi-cel; 10% with new or worsening cardiomyopa…
RT @RShouval: Cardiomyopathy post-CAR more common than we thought. 187 pts; 94% treated with axi-cel; 10% with new or worsening cardiomyopa…
RT @RShouval: Cardiomyopathy post-CAR more common than we thought. 187 pts; 94% treated with axi-cel; 10% with new or worsening cardiomyopa…
RT @RShouval: Cardiomyopathy post-CAR more common than we thought. 187 pts; 94% treated with axi-cel; 10% with new or worsening cardiomyopa…
RT @RShouval: Cardiomyopathy post-CAR more common than we thought. 187 pts; 94% treated with axi-cel; 10% with new or worsening cardiomyopa…
RT @RShouval: Cardiomyopathy post-CAR more common than we thought. 187 pts; 94% treated with axi-cel; 10% with new or worsening cardiomyopa…
RT @RShouval: Cardiomyopathy post-CAR more common than we thought. 187 pts; 94% treated with axi-cel; 10% with new or worsening cardiomyopa…
RT @RShouval: Cardiomyopathy post-CAR more common than we thought. 187 pts; 94% treated with axi-cel; 10% with new or worsening cardiomyopa…
Cardiomyopathy post-CAR more common than we thought. 187 pts; 94% treated with axi-cel; 10% with new or worsening cardiomyopathy (proven by echo) https://t.co/ljVKIOCfiq
Very cool.
RT @CircAHA: #ResearchLetter: Chimeric Antigen Receptor T-cell Therapy Associated Cardiomyopathy in Patients with Refractory or Relapsed No…
RT @CircAHA: #ResearchLetter: Chimeric Antigen Receptor T-cell Therapy Associated Cardiomyopathy in Patients with Refractory or Relapsed No…
RT @CircAHA: #ResearchLetter: Chimeric Antigen Receptor T-cell Therapy Associated Cardiomyopathy in Patients with Refractory or Relapsed No…
RT @CircAHA: #ResearchLetter: Chimeric Antigen Receptor T-cell Therapy Associated Cardiomyopathy in Patients with Refractory or Relapsed No…
RT @CircAHA: #ResearchLetter: Chimeric Antigen Receptor T-cell Therapy Associated Cardiomyopathy in Patients with Refractory or Relapsed No…
RT @CircAHA: #ResearchLetter: Chimeric Antigen Receptor T-cell Therapy Associated Cardiomyopathy in Patients with Refractory or Relapsed No…
#ResearchLetter: Chimeric Antigen Receptor T-cell Therapy Associated Cardiomyopathy in Patients with Refractory or Relapsed Non-Hodgkin Lymphoma. Learn more: https://t.co/j2Ug8WOMz3 #AHAJournals @SarjuGanatraMD @TariqAzamMD @salimhayek
RT @SarjuGanatraMD: Our study on Chimeric Antigen Receptor T-Cell Therapy–Associated #Cardiomyopathy in Patients With Non-Hodgkin #lymphoma…
RT @SarjuGanatraMD: Our study on Chimeric Antigen Receptor T-Cell Therapy–Associated #Cardiomyopathy in Patients With Non-Hodgkin #lymphoma…
RT @SarjuGanatraMD: Our study on Chimeric Antigen Receptor T-Cell Therapy–Associated #Cardiomyopathy in Patients With Non-Hodgkin #lymphoma…
Chimeric Antigen Receptor T-Cell Therapy-Associated Cardiomyopathy in Patients With Refractory or Relapsed Non-Hodgkin Lymphoma. #lymphoma #lymsm https://t.co/JWrFnC0zwd
RT @SarjuGanatraMD: Our study on Chimeric Antigen Receptor T-Cell Therapy–Associated #Cardiomyopathy in Patients With Non-Hodgkin #lymphoma…
RT @SarjuGanatraMD: Our study on Chimeric Antigen Receptor T-Cell Therapy–Associated #Cardiomyopathy in Patients With Non-Hodgkin #lymphoma…
RT @SarjuGanatraMD: Our study on Chimeric Antigen Receptor T-Cell Therapy–Associated #Cardiomyopathy in Patients With Non-Hodgkin #lymphoma…
Very interesting study!
RT @TariqAzamMD: Our letter in @CircAHA on CAR-T related cardiomyopathy - this is the clinical ? that sparked my interest in #CardioOncolog…
RT @TomasNeilan: Great study by @SarjuGanatraMD, @salimhayek and colleagues from @umichmedicine @BrighamWomens and @DanaFarber showing that…
Congrats @SarjuGanatraMD @salimhayek and team! Great work! Opening for longer term outcomes studies, along the good question from @onco_cardiology
Congratulations!!
RT @SarjuGanatraMD: Our study on Chimeric Antigen Receptor T-Cell Therapy–Associated #Cardiomyopathy in Patients With Non-Hodgkin #lymphoma…
RT @SarjuGanatraMD: Our study on Chimeric Antigen Receptor T-Cell Therapy–Associated #Cardiomyopathy in Patients With Non-Hodgkin #lymphoma…
RT @datsunian: Great #cardioonc work on #cart CTX from @SarjuGanatraMD @salimhayek and colleagues! @mvrothberg @DrDariaGaut @TomasNeilan @…
RT @datsunian: Great #cardioonc work on #cart CTX from @SarjuGanatraMD @salimhayek and colleagues! @mvrothberg @DrDariaGaut @TomasNeilan @…
Great #cardioonc work on #cart CTX from @SarjuGanatraMD @salimhayek and colleagues! @mvrothberg @DrDariaGaut @TomasNeilan @saadhealth @A_SteinMerlob @Nguyenckebach @dustintlee
RT @SarjuGanatraMD: Our study on Chimeric Antigen Receptor T-Cell Therapy–Associated #Cardiomyopathy in Patients With Non-Hodgkin #lymphoma…
RT @SarjuGanatraMD: Our study on Chimeric Antigen Receptor T-Cell Therapy–Associated #Cardiomyopathy in Patients With Non-Hodgkin #lymphoma…
RT @TariqAzamMD: Our letter in @CircAHA on CAR-T related cardiomyopathy - this is the clinical ? that sparked my interest in #CardioOncolog…
RT @TomasNeilan: Great study by @SarjuGanatraMD, @salimhayek and colleagues from @umichmedicine @BrighamWomens and @DanaFarber showing that…
RT @TomasNeilan: Great study by @SarjuGanatraMD, @salimhayek and colleagues from @umichmedicine @BrighamWomens and @DanaFarber showing that…
Very exciting work!
Great study by @SarjuGanatraMD, @salimhayek and colleagues from @umichmedicine @BrighamWomens and @DanaFarber showing that at least 10% develop a cardiomyopathy after CAR-T. Higher risk in older and pre-existing CV disease
RT @TariqAzamMD: Our letter in @CircAHA on CAR-T related cardiomyopathy - this is the clinical ? that sparked my interest in #CardioOncolog…
@SarjuGanatraMD fantastic!
RT @SarjuGanatraMD: Our study on Chimeric Antigen Receptor T-Cell Therapy–Associated #Cardiomyopathy in Patients With Non-Hodgkin #lymphoma…
RT @SarjuGanatraMD: Our study on Chimeric Antigen Receptor T-Cell Therapy–Associated #Cardiomyopathy in Patients With Non-Hodgkin #lymphoma…
RT @SarjuGanatraMD: Our study on Chimeric Antigen Receptor T-Cell Therapy–Associated #Cardiomyopathy in Patients With Non-Hodgkin #lymphoma…
#CardioOncology @md_addison
@salimhayek @DanaFarber @bethisraellahey @UMich @CircAHA
RT @SarjuGanatraMD: Our study on Chimeric Antigen Receptor T-Cell Therapy–Associated #Cardiomyopathy in Patients With Non-Hodgkin #lymphoma…
Our study on Chimeric Antigen Receptor T-Cell Therapy–Associated #Cardiomyopathy in Patients With Non-Hodgkin #lymphoma.Incidence 10%, median 12 days after #CART. Older age, CV risk factors,#CVD and higher grade CRS are risk factors.#CardioOncology https:
RT @TariqAzamMD: Our letter in @CircAHA on CAR-T related cardiomyopathy - this is the clinical ? that sparked my interest in #CardioOncolog…
Our letter in @CircAHA on CAR-T related cardiomyopathy - this is the clinical ? that sparked my interest in #CardioOncology - thanks to @salimhayek I was able to be part of a multicenter team studying it https://t.co/hRFj7bVc2g